ATACAS wins Clinical Trial of the Year

Learn more about the award-winning ANZCA-led international study into Aspirin and Tranexamic Acid for Coronary Artery Surgery.
 
The international Aspirin and Tranexamic Acid for Coronary Artery Surgery (ATACAS) trial led by ANZCA Fellow Professor Paul Myles, head of the Department of Anaesthesia and Perioperative Medicine at Monash and the Alfred Hospital, has been awarded the Clinical Trial of the Year Award.

With funding provided by the ANZCA Research Foundation and the National Health and Medical Research Council ANZCA played a key role in the ATACAS trial which was led by ANZCA’s Clinical Trials Network and co-ordinated by the Alfred Hospital and Monash University. 

The trial found that taking Aspirin before having open heart surgery does not result in a higher bleeding risk but instead protects against heart attack and stroke. It also found that tranexamic acid (a medication to reduce bleeding after cardiac surgery) does not increase thrombosis after open heart surgery. 

The trial involved 30 hospitals in seven countries and 4600 patients participated.

The ACTA award, which was presented by the Federal Minister for Health, Greg Hunt, in Sydney on Friday May 19, recognises the importance of research and its direct influence on improving patient outcomes.
ACTA Chair, Professor John Zalcberg, said it was an “honour to celebrate the highest calibre of clinical trials conducted not only in Australia but on the international stage.’’



“We are privileged to have a world-class clinical community dedicated to addressing the gaps in our healthcare system to ensure we are delivering world-class care to all Australians.”

 
Copyright © Australian and New Zealand College of Anaesthetists.